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Hepatocellular carcinoma (HCC) is the 6th most common cancer and the 4th leading cause 
of carcinoma-related death worldwide; yet there no curative chemotherapy strategy available 
for unresectable HCC.  Bortezomib (BTZ) is a proteasome inhibitor that is FDA-approved for 
multiple myeloma and certain subtypes of chronic myelogenous leukemia; and in drug 
screening tests it shows promising potency in HCC cells. Systemic administration at 
required doses proves to be toxic in mice, however, repeated intra-tumoral injections results 
in tumor regression.  The objective of this study is to develop a BTZ-loaded nanoparticle 
that can lower the systemic toxicity through local release of BTZ over several days. The 
BTZ-loaded nanoparticles were prepared by a facile assembly technique combining flash 
nanocomplexation (FNC) and flash nanoprecipitation (FNP), achieving high uniformity, 
stability, and adjustability by controlling the input parameters during preparation process. 
In the pilot in vivo study, the BTZ-loaded nanoparticles demonstrated local retention for 
more than 10 days in tumor tissue following intratumoral injection and exerted similar 
tumor-killing effect with same dose, yet less injection frequency as compared to free BTZ. 
The BTZ-loaded nanoparticles exhibited potential as a locoregional delivery system to 
provide a new therapeutic modality for future HCC treatment. 
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Background and Significance 
 
In 2019, the incidence of liver cancer is estimated to be about 42,000 in United States 
and 840,000 worldwide, posing a great threat to human health. Among all the liver 
cancer patients, hepatocellular carcinoma (HCC) accounts for 80–85% of all cases of 
primary liver cancers[1]. However, there is currently no curative chemotherapy strategy 
on the market for unresectable advanced cancer. Some experts have even hypothesized 
that HCC is “not druggable”[2]. Our collaborator Prof. Selaru and team at Johns 
Hopkins Medical School have established 37 primary patient-derived organoid (PDO) 
cultures from resected HCC tissues; and tested a library of Food and Drug 
Administration (FDA-approved cancer drugs across all 37 PDO cultures. They found 
that bortezomib (BTZ), a proteasome inhibitor that is approved for multiple myeloma 
and some forms of chronic myelogenous leukemia (CML) is highly effective across all 
tested PDO lines. Furthermore, BTZ has proven to be more effective than any of the 
currently approved FDA drugs for unresectable HCCs across all 37 PDO lines. 
However, BTZ under high dose systemic exposure has strong side effect that can lead 
to organ dysfunction and even lethality[3, 4]. This limitation hampers its potential 
clinical translation. Therefore, in order to improve the therapeutic efficiency of the drug, 
we aim to develop a strategy to decrease the systemic toxicity and expand the 
therapeutic window by developing a sustained release formulation of BTZ that can 
provide a local delivery of the drug in a controlled manner[5-8]. 
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Currently, common strategies for the delivery of BTZ include the application of 
polymer, mesoporous silica, graphene oxide and liposomal nanoparticle systems[9-12]. 
However, few of them have focused on the construction of a local sustained release 
formulation of BTZ, therefore it is of great significance to develop an effective 
formulation that can be translated into clinical application in future use. There is a recent 
report using poly(lactic-co-glycolic acid) (PLGA) nanoparticle as carrier to achieve an 
extended release of BTZ. However, the complicated emulsion method employed has 
compromised the stability and reproducibility of the nanoparticle preparation and thus 
rendered it hard to reproduce[11]. Here, we report a new nanoparticle formulation 
prepared under facile process using our newly developed sequential Flash 
Nanocomplexation (FNC)/Flash Nanoprecipitation (FNP) technique. We explored the 
possibility of constructing a quaternary nanoparticle structure combining a ternary 
complex of tannic acid (TA), BTZ and ovalbumin (OVA) as core with coating of PEG-
PLGA polymer matrix.  
Tannic acid (TA) has been reported as a carrier in nanoparticulate protein release system, 
owing to its unique structure and ability to form hydrogen bonds with proteins[13, 14]. 
Similar to its binding with protein, the polyphenol structure of TA provides various 
bonding capacity towards BTZ including π-π stacking, hydrophobic interaction, and 
hydrogen bond, which makes it an ideal choice as a “BTZ cage” in the nanoparticle 
system[12, 15, 16]. The addition of OVA was expected to lower the highly negatively 
charged complex surface and increase the hydrophobicity thus helps with the PEG-
PLGA coating. The sequential FNC/FNP platform can achieve a controlled nanoparticle 
assembly and release behavior by manipulating formulation parameters including 
mixing speed, pH, and concentrations, avoiding cumbersome operations typically used 
in the emulsion methods.  This new method and new nanoparticle system hold great 
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clinical translation potential due to the obvious advantages in terms of particle size 
uniformity, high loading capacity, good control over release duration, reproducibility, 
and high scalability. We also studied the retention rate of BTZ-loaded nanoparticles and 
the tumor-killing effect in patient-derived xenograft (PDX) via intratumoral injection to 
test the potential therapeutic outcomes of local sustained delivery approach for BTZ.   
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        Chapter 2 
 
Experimental Approach and Methods 
2.1 Devices and materials 
Bortezomib was purchased from LC Laboratories (Woburn, MA, U.S.). Tannic acid 
(TA) and albumin from chicken egg white (ovalbumin) was purchased from Sigma-
Aldrich (St. Louis, MO, U.S.). 5k-20k polyethylene glycol–poly(lactic acid-co-glycolic 
acid)(PEG-PLGA) was purchased from Poly SciTech®, Akina (West Lafayette, IN, 
U.S). Float-A-Lyzer® G2 dialysis device was purchased from Repligen (Waltham, MA, 
USA). Ultrafiltration tube was purchased from Sartorius (Göttingen, Germany). NE-
4000 programmable multi-channel syringe pump was purchased from New Era Pump 
Systems, Inc (Farmingdale, NY, U.S.). 5 ml NORM-JET® syringe was purchased from 
VWR™ (Radnor, PA, U.S.). Thermo Scientific™ Hypersil™ BDS C18 HPLC 
Columns (4.6 mm×250 mm) was purchased from Thermo Fisher Scientific (Waltham, 
MA, U.S.). HPLC grade water, HPLC grade acetonitrile were purchased from Thermo 
Fisher Scientific (Waltham, MA, U.S.).  
 
2.2 Preparation of BTZ-loaded nanoparticles 
BTZ-loaded nanoparticles were prepared using a sequential FNC/FNP process (Figure. 
1). The working solutions were prepared as follow: (1) BTZ was dissolved in a solvent 
composed of dimethyl sulfoxide (DMSO):distilled water (10:90, v/v) at a concentration 
of 1 mg/ml; (2) Tannic acid (TA) was dissolved in distilled water (pH = 5) at a 
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concentration of 4 mg/ml; (3) OVA was dissolved in distilled water (pH = 7.5) at a 
concentration of 1 mg/ml; and (4) PEG-PLGA was dissolved in pure acetonitrile at a 
concentration of 3, 5, or 7 mg/ml. Controlled by two digital syringe pumps, solutions 
of BTZ and TA were simultaneously injected into the two-inlet confined impingement 
jets (CIJ) mixer under a flow rate of 1, 3, 5 ml/min to form the BTZ-TA complex (Step 
1, Figure 1). Then the BTZ/TA complex and OVA were simultaneously injected into 
the two-inlet CIJ mixer under a flow rate of 1, 8, 15 ml/min to coat the complex with a 
layer of OVA (Step 2). Finally, the BTZ/TA complex or OVA/BTZ-TA complex, water 
and PEG-PLGA were injected into a 3-inlet multi inlet vortex mixer for the FNP step 
under a flow rate of 3, 6, 10 ml/min (Step 3). The first 1 ml of the efflux mixture may 
contain less well-defined nanoparticles during the initial establishment of the steady 
flow, and therefore was discarded. The resulted nanoparticles were dialyzed in a 3.5-




In order to find the optimal formulation based on out sequential FNC/FNP platform, the 
size uniformity and surface charge of BTZ-TA, BTZ-TA-OVA nanocomplex and BTZ-
loaded nanoparticle were measured by the dynamic light scattering (DLS) analysis using 
Malvern Zetasizer Nano ZS at 25 ℃. To evaluate the encapsulation efficiency (EE) and 
loading level (LD), 5 ml of freshly prepared BTZ-loaded nanoparticle was dialyzed in 
DI water using 3.5 kDa dialysis bag for 4 hours and then lyophilized using a FreeZone 
Triad Benchtop Freeze Dryers (Labconco, USA) at 25 ℃ and 10 Pa for 36 hours. The 
dried nanoparticles were weighed and then dissolved in 5 ml acetonitrile and measured 
by HPLC using UV-vis spectroscopy at 280 nm to determine the remaining 
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(encapsulated) BTZ concentration. All measurements were performed in triplicates. 
𝐸𝐸𝐸𝐸 (%)  =  �
𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑜𝑜 𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒 𝐵𝐵𝐵𝐵𝐵𝐵
𝐵𝐵𝑚𝑚𝑚𝑚𝑒𝑒𝑒𝑒 𝑒𝑒𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑜𝑜 𝐵𝐵𝐵𝐵𝐵𝐵 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
�  × 100%                  (1) 
 
 
𝐿𝐿𝐿𝐿 (%)  =  �
𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑜𝑜 𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑒𝑒 𝐵𝐵𝐵𝐵𝐵𝐵
𝐵𝐵𝑚𝑚𝑚𝑚𝑒𝑒𝑒𝑒 𝑒𝑒𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑜𝑜 𝑒𝑒𝑙𝑙𝑚𝑚𝑒𝑒ℎ𝑖𝑖𝑒𝑒𝑖𝑖𝑖𝑖𝑒𝑒𝑒𝑒 𝑚𝑚𝑒𝑒𝑚𝑚𝑚𝑚𝑒𝑒𝑒𝑒𝑛𝑛𝑚𝑚𝑖𝑖𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒




2.4 Storage stability 
The storage stability of BTZ-loaded nanoparticles was evaluated both in the solution 
form and the lyophilized form. The colloidal stability was evaluated by storing BTZ-
nanoparticle suspension in 4 ℃ for 30 days and measuring the change in size and surface 
charge. The lyophilization stability was evaluated by applying the same lyophilization 
protocol (with addition of 9.5% trehalose as cryoprotectant). The freeze-dried powder 
was stored at -80 ℃. After 30 days, the size and polydispersity index of the lyophilized 
nanoparticles were monitored upon reconstitution. 
 
2.5 In vitro release of BTZ from nanoparticles 
The in vitro release behaviors of BTZ-loaded nanoparticles were conducted using a 
dialysis method. Briefly, 1 ml of BTZ-loaded nanoparticle suspension was pipetted into 
a 100-kDa dialysis tube and incubated in 9 ml of PBS (10 mM, pH 7.4, with 0.1% tween 
20) at 37 ℃ on a shaker at 100 rpm. At predominant time points (8, 16, 32, 56, 80, 104, 
128 hours), 0.2 ml of the release medium was taken out and equivalent volume of fresh 
PBS was added. The concentration of released BTZ in the collected sample was 
measured using HPLC. The mobile phase composed of acetonitrile: water (60/40, v/v), 
maintaining a flow rate of 1 ml/min. The UV detector was set at 280 nm for absorption 




2.6 MTT assay 
Cells from three different patient-derived HCC organoids were separately seeded in a 
96-well plate at a density of 1000 cells per well and allow to grow for 24 hours. Then, 
free BTZ (1, 0.1, 0.01 μM), NP-3 (1, 0.1, 0.01 μM) and same volume of PBS were 
added into each well and incubated for 4 and 8 days. After 4 incubation, medium was 
removed, and wells were washed with PBS. The MTT reagent was dissolved in medium 
to a final concentration of 0.5 mg/ml in each well, followed by incubation for 4 hours 
at 37°C. After removing the MTT-contained medium, DMSO solution (150 μL/well) 
was added, and the plate was shaken on a microplate stirrer for 10 minutes to dissolve 
the crystal. The OD value of each well was detected by a microplate reader (detection 
wavelength 570 nm). 
 
2.7 In vivo retention at injection site using Cy 7.5-labelled 
nanoparticles  
Cy 7.5 carboxylic acid was used to label PEG-PLGA as previously described[17]. Cy 
7.5-labelled nanoparticles were prepared following the same formulation above with 
dye-labelled PEG-PLGA. The retention effect of nanoparticles was assessed using 
patient derived xenograft (PDX) model. Briefly, fresh human tumor tissue was harvested 
from HCC patients, then cut in small pieces (2×2×2 mm3) and implanted subcutaneously 
in the right flank of NSG mice. Once tumors grew, a similar process (harvesting tumors 
from mice, mincing and inserting in new mice) was implemented. Mice at the 5th 
passage of PDX were utilized in this experiment. After implantation subcutaneously, the 
tumors were allowed to grow to approximately 1,000 mm3. Five mice were subjected to 
intratumoral injection of 100 μL of Cy 7.5-labelled nanoparticles suspension, and the 
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biodistribution of Cy 7.5-nanoparticle was revealed by near infrared imaging using the 
IVIS system (PerkinElmer, US) with λex 780 nm and λem 810 nm for 12 days post-
administration. The retention rate of nanoparticles at injection site was calculated by 
comparing the remaining fluorescence intensity to the that of the original time point. 
 
2.8 In vivo therapeutic effect of BTZ-loaded nanoparticles 
The therapeutic effect of BTZ-loaded nanoparticles was assessed by monitoring the 
tumor-killing effect in PDX model mice following intratumoral injection. Briefly, mice 
were randomized to 3 groups with 5 mice in each group. Two treatment groups were 
administrated with 100 µL of free BTZ drug (0.5 mg/kg) twice a week, and 100 µL of 
BTZ-loaded nanoparticles (1 mg/kg) once a week, respectively. The control group was 
treated with 100 µL of PBS. The tumor size and body weight of the mice in different 
groups were measured two times per week throughout the 4-week period. The mice were 






Experimental Results and Discussion 
3.1 Formulation screening and characterization of the BTZ-loaded 
nanoparticles 
 
Figure 1. Schematic illustration of the sequential FNC /FNP method utilized in the BTZ-
loaded nanoparticle preparation process. 
 
The nanoparticle was assembled by a sequential FNC/FNP process as shown in Figure 1, in which 
the first step is to generate a TA-BTZ complex. We found that the uniformity of TA-BTZ complex 
is closely associated with flow rate as higher mixing rate will result in poorer size distribution 
(Figure 2A). We speculated that the complexation between TA and BTZ requires a certain 
reaction time, thus lower flowrate allowed the complexation process to happen within the mixing 
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chamber and render a uniform distribution of the BTZ-TA nanocomplex. Therefore, the flowrate 
of step one was set as 1 ml/min. Comparing to the flow rate to form TA-BTZ complex (1 ml/min), 
the formation of OVA-TA-BTZ complexes required a relatively high flow rate (15 ml/min) to 
ensure a uniform nanocomplex (Figure 2B), which necessitated the two-step FNC process instead 
of a one-step ternary mixing. As shown in Figure 2C, the final FNP step also requires a relatively 
high flow rate to render a uniform size distribution. Our interpretation is that the formation of 
OVA-TA-BTZ complex as well as the precipitation of polymer in the FNP step is relatively fast, 
therefore they need a higher mixing speed, which allows for a homogeneous distribution of all 
components within milliseconds for generating uniform nanoparticles instead of forming local 
aggregation due to inefficient mixing[18, 19].   
 
Figure 2. Formulation screening of the sequential FNC/FNP process. (A) Size distribution of TA-BTZ 
complex under different flow rate. (B) Size distribution of TA-BTZ-OVA complex under different flow rate. (C) 
Size distribution of BTZ-loaded nanoparticle under different flow rate. 
 
The optimized BTZ-loaded nanoparticle showed a narrow size distribution (Figure 3A) and with 
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high encapsulation efficiency (~90%) and loading level (3% - 5%) of BTZ. We observed an 
increasing trend of particle size and surface charge with the addition of each component (Figure 
3B), which indirectly suggests a construction of the BTZ-loaded nanoparticle in a stepwise 
assembly manner. The BTZ-TA nanocomplexes carried a high negative surface charge (-44.2 ± 
0.3 mV), which is unfavorable for the coating of PEG-PLGA. By incorporating OVA into the 
complexes, the average surface charge was decreased to -20.8 mV. We expected that 
incorporation of OVA plays an essential role to enhance the compatibility between BTZ-TA 
complex and PEG-PLGA by decreasing surface charge and increasing hydrophobicity, thus 
enhanced the coating of outer polymeric matrix[20, 21]. The core-shell structure was the revealed 
by the TEM imaging shown in Figure 3C. 
These nanoparticles also showed excellent colloidal stability in water for 30 days under 4 ℃ and 
preserved the same physical profile after reconstituting lyophilized samples that had been in 
storage at -20 ℃ for 1 months (Table 1). 
 
 
Figure. 3 Characterization of BTZ-loaded nanoparticles. (A) Size distribution of BTZ-loaded nanoparticles; 
(B) Surface charge and size change of nanoparticle along each step. (C) Transmission electron microscopy 





Table 1. Characteristics of freshly prepared vs. lyophilized-and-reconstituted BTZ-loaded nanoparticles. 
Parameter Freshly prepared Reconstituted 
Average size (nm) 72.3 ± 1.8 80.2 ± 2.4 
Average zeta potential (mV) -36.5 ± 0.8 -38.2 ± 0.5 
Polydispersity index (PDI) 0.13 ± 0.01 0.15 ± 0.01 
Rehydration time (sec) - < 15 
All data are shown as means ± S.D. (n = 3). 
 
 
3.2 In vitro release of BTZ-loaded nanoparticles 
 
Figure 4. In vitro release study of different BTZ nano-formulations. BTZ-TA complex and BTZ-
TA-OVA complex without PEG-PLGA coating; NP-0 refers to TA/BTZ complex coated directly 
with PEG-PLGA; NP-1, NP-2, NP-3 refer to BTZ/TA/OVA/PEG-PLGA nanoparticle prepared 
under different PEG-PLGA concentrations. The results are presented as mean ± S.D. (n = 3).  
 
As shown in Figure 4, we compared the release behavior of different formulations in 
PBS (pH=7.4) under 37 ℃ for 128 hours. NP-0 refers to nanoparticles made by a two-
step FNC/FNP method, in which BTZ-TA complex directly went through the FNP 
process without OVA complexation. NP-1, NP-2, NP-3 refer to BTZ-loaded 































nanoparticles made by different concentration of PEG-PLGA (3, 5, 7, respectively). It 
is worth noting that NP-0 did not yield any measurable difference in release profile as 
compared with BTZ-TA and BTZ-TA-OVA nanocomplexes, suggesting a poor coating 
efficiency of PEG-PLGA onto the BTZ-TA complex surface. In contrast, NP-1, NP-2, 
NP-3 showed gradual extension of the release duration and lower release rate of BTZ 
from the nanoparticles. NP-3 achieved a release duration of around 5 days.  These results 
are consistent with the hypothesis that BTZ-TA nanocomplexes carry too much surface 
charge to facilitate coating of the hydrophobic PLGA; and the incorporation of OVA 
effectively reduced the surface charge and polarity, thus increasing the rate of 
heterogenous nucleation of PEG-PLGA on the complex core[22, 23]. Furthermore, BTZ 
release rate can be reduced by increasing polymer concentration in the final coating 
process. This quaternary nanoparticle system endowed a high degree of flexibility in 
tuning release profile to satisfy various treatment options. This study provided the 






3.3 In vitro efficacy of BTZ-loaded nanoparticles 
 
Figure 5. In vitro activity evaluation of BTZ-loaded nanoparticles. Cell viability results in 
different concentration of BTZ-loaded nanoparticles and free BTZ after 4 days or 8 days. The results 
are presented as mean ± S.D. (n = 3). 
 
 
We first studied the in vitro bioactivity of BTZ-loaded nanoparticles by conducting MTT 
assay using different doses of BTZ. The tumor killing ability of BTZ-loaded 
nanoparticles was measured on three different patient derived cancer cells and compared 
with different formulations. As shown in Figure 5, there was no significant difference 
in cell viability between the cells treated with BTZ-loaded nanoparticles and free BTZ, 
indicating that the tumor-killing ability of BTZ-loaded nanoparticles was not 
compromised by the nano-formulating process and the sustained release manner. These 
results provide strong justification for in vivo testing to assess the long-acting tumor 




3.4 In vivo retention effect in tumor tissue following intratumoral 
injection of BTZ-loaded nanoparticles 
         
.  
Figure 6. Biodistribution of the fluorescent dye-labeled nanoparticles after intra-tumoral 
injection. (A) In vivo fluorescence imaging of mice at different time points (0 – 12 d) after a single 
intratumoral injection of Cy 7.5-labelled nanoparticles. (B) Semi-quantification of fluorescence 
intensity of the Cy 7.5-labelled nanoparticle at injection site. The results are presented as mean ± 
S.D. (n = 5) 
 
Our proposed aim to achieve a local sustained release using BTZ-loaded nanoparticles 
relies on that the nanoparticles will be sufficiently retained in the tumor tissue , rather 
than rapidly cleared into systemic circulation. Due to the enhanced permeability and 
retention (EPR) effect, nanosized agents tend to be enriched and retained in the tumor 
tissue[24-26]. In order to test our formulated BTZ for its ability to be retained in the 
tumor mass, we monitored the release of fluorescently dye-labeled nanoparticles after 
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intratumoral injection for 12 days. As shown in Figure 6A, the fluorescence intensity 
was maintained at a high level throughout the experiment, indicating an excellent 
retention of the nanoparticles in the tumor mass. This finding was further confirmed by 
the semi-quantitative analysis shown in Figure 6B, which ensured that the BTZ could 
be slowly released within the tumor tissue during the treatment period considering the 
retention time of more than 12 days is much longer than the release duration (~5 days). 
 
3.5 In vivo tumor-inhibition effect of BTZ-loaded nanoparticles in 
patient-derived xenograft (PDX) model 
 
Figure 7. In vivo therapeutic outcomes of BTZ-loaded nanoparticles. (A) Relative tumor size as 
compared to original point in different treatment groups. (B) Relative body weight of mice as 
compared to original point in different groups. (C) Tumor weight measured at the end point of the 
treatment. (D) Gross pictures of the tumor tissues in each treatment groups. 
 








              PBS (n=5) 
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potency in inhibiting tumor growth following intratumoral injection (Figure 8). The 
dosages of free BTZ and BTZ-loaded nanoparticles were determined by a preliminary 
study assessing the tolerated dose of free BTZ to be 1 mg/kg, which killed mice within 
two days. In comparison, BTZ-loaded nanoparticles were tolerated well at the same 
dose. In this pilot study, we selected a dose of 0.5 mg/kg given twice weekly for free 
BTZ treatment, and doubled dose for BTZ-loaded nanoparticle treatment at a longer 
interval (1 mg of BTZ/kg, once per week). As shown in Figure 7A, the average tumor 
size in the control group increased by 5 folds over a 4-week period. Both the free BTZ 
and BTZ-loaded nanoparticle treatment successfully suppressed tumor growth 
completely. It appears that the BTZ-nanoparticles had a stronger tumor inhibiting effect 
at early time points (Days 6 to 14), considering that same total dose was given. 
Unfortunately, there are two mice in BTZ nanoparticle treatment group and one mouse 
in free BTZ group got pregnant near the end experiment. The tumor of pregnant mice 
started growing again even with treatments, therefore the data of which were removed 
from the results. There were no measurable differences in body weights of mice among 
all treatment groups throughout the entire treatment period (Figure 7B), except that the 
body weight of mice in the control group treated with PBS gradually increased after 2 
weeks, presumably due to the overgrowth of tumor tissue. All mice were euthanized 
after 28 days and tumor tissue were collected to measure tumor mass directly (Figure 
7C-D). The results (Figure 7C) matched the size measurement (Figure 7A) with a high 
level of consistence. Since all mice were originally implanted with similar size of tumor 
tissue, the dramatic difference between control group and treatment groups further 
demonstrated the significant tumor-killing ability of both BTZ formulations. More 
importantly, the BTZ-loaded nanoparticle treatment given at a lethal dose of BTZ (1 
mg/kg), but did not yield any mortality, indicating the nano-formulated drug was 
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effective in lowering the systemic toxicity comparing to its free form as a result of a 
sustained release mechanism. Such a treatment option with a reduced systemic toxicity 
combining with high tumor-inhibition potency and less frequent administration, will 





Chapter 4  
 
Conclusion and Outlook 
 
We have developed a BTZ-loaded nanoparticle formulation that can achieve sustained 
release of BTZ using a new nanoencapsulation method that offers the advantages of 
continuous, tunable, and scalable manufacturing features. We established correlations 
between manufacturing parameters, nanoparticle characteristics, and drug release 
properties of the BTZ nanoparticles. By controlling the input parameters during 
manufacturing process, we are able to control the BTZ release behavior of 
nanoparticles. We have showed that this BTZ-loaded nanoparticle system could 
significantly lower the systemic toxicity, extend the retention of nanoparticles at the 
injection site to achieve local delivery, and show strong tumor inhibition effect with the 
same total dosage as the free drug, but given at a less dosing frequency. This new 
formulation can improve therapeutic efficacy and patient compliance.  
Further improvement will focus on controlling the assembly kinetics and internal 
structure of the nanoparticles through gaining insight into the assembly mechanism and 
polymer coating kinetics, thus achieving higher BTZ loading level and tighter control 
of BTZ release profile. A well-defined nanoparticle structure will help us explore the 
full potential of the formulation. Beyond intratumor delivery, we plan to investigate the 
effectiveness of systemically administrated nanoparticles (such as intravenous 
injection) on delivery efficiency to the tumor that have multiple nodules in the liver (i.e. 
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